Roth Capital affirms Regeneron (Nasdaq: REGN) with a Buy rating and $520 price target following Q2 results and updated guidance ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Regeneron Pharma (REGN) PT Trimmed to $511 at Leerink PartnersAugust 5, 2016 8:03 AM Baird Downgrades Regeneron Pharma (REGN) to Neutral; EPS Expectations Will Be Hard to MeetAugust 5, 2016 6:44 AM Form 10-Q REGENERON PHARMACEUTICAL For: Jun 30August 4, 2016 7:33 AM Form 8-K REGENERON PHARMACEUTICAL For: Aug 04August 4, 2016 7:20 AM Regeneron (REGN) Tops Q2 EPS by 17c; Updates FY16 ExpectationsAugust 4, 2016 6:32 AM Regeneron Reports Second Quarter 2016 Financial and Operating ResultsAugust 4, 2016 6:30 AM